Neurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy
Preprint
- 9 June 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Neurofibromatosis Type 1 (NF1) is a genetic disorder characterized by a wide range of clinical manifestations, including café-au-lait macules, cutaneous neurofibromas, and an increased risk of certain malignancies. Historically, there has been no approved medical therapy specifically aimed at achieving tumor shrinkage or regression. Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection. Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1. This review highlights the pathophysiology of NF1, the therapeutic role of MEK inhibitors, and presents a detailed case study of a patient treated with selumetinib, a novel MEK inhibitor. While the therapeutic potential of selumetinib has been demonstrated in preclinical and clinical studies, including those involving Japanese patients, this review aims to evaluate its application in real-world clinical practice. A comprehensive discussion of the case study provides insights into the efficacy, safety, and clinical challenges associated with selumetinib treatment, offering valuable perspectives for its use in managing NF1.Keywords
All Related Versions
- Version 1, 2025-06-09, Preprints
- Published version: Journal of Clinical Medicine, 14 (14), 5071.
This publication has 21 references indexed in Scilit:
- Multiparametric whole-body MRI of patients with neurofibromatosis type I: spectrum of imaging findingsSkeletal Radiology, 2024
- Mutational spectrum of NF1 gene in 24 unrelated Egyptian families with neurofibromatosis type 1Molecular Genetics & Genomic Medicine, 2021
- Neurofibromatosis type 1: New developments in genetics and treatmentJournal of the American Academy of Dermatology, 2021
- Clinical Pharmacokinetics and Pharmacodynamics of SelumetinibClinical Pharmacokinetics, 2020
- Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapyNature Communications, 2020
- The Diagnosis and Management of Neurofibromatosis Type 1Medical Clinics of North America, 2019
- Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisSkeletal Radiology, 2019
- Neurofibromatosis 1 Diagnosed in Mother Only after a Follow-up of Her DaughterIndian Journal of Plastic Surgery, 2019
- Prevalence of neurofibromatosis type 1 in the Finnish populationGenetics in Medicine, 2018
- Carbon Dioxide Laser Treatment of Cutaneous NeurofibromasDermatology and Therapy, 2012